Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acquired plasma factor XIII deficiencies

A Tosetto1, G Castaman, F Rodeghiero

  • 1Department of Hematology, San Bortolo Hospital, Vicenza, Italy.

Haematologica
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply.

Journal of thrombosis and haemostasis : JTH·2018
Same author

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.

Journal of thrombosis and haemostasis : JTH·2018
Same author

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Thrombopoietin receptor agonists in hereditary thrombocytopenias.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Haematologica·2026
Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026
Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026
Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
See all related articles

Acquired deficiencies in coagulation factor XIII (FXIII) can cause severe bleeding. Prompt diagnosis and treatment are crucial for patients with FXIII inhibitors, while the role of FXIII levels in other conditions is also discussed.

Area of Science:

  • Hematology
  • Coagulation Science
  • Hemostasis

Background:

  • Coagulation factor XIII (FXIII) is essential for fibrin stabilization, the final stage of coagulation.
  • Defective fibrin stabilization, as seen in congenital FXIII deficiency, leads to severe bleeding disorders.
  • Acquired FXIII deficiencies present unique challenges in diagnosis and management.

Purpose of the Study:

  • To review the pathophysiology, clinical presentation, and therapy of acquired plasma FXIII deficiencies.
  • To highlight the urgency of diagnosing and treating severe FXIII deficiency caused by inhibitors.
  • To discuss the significance of reduced FXIII levels in other conditions and the potential for substitution therapy.

Main Methods:

  • Literature review of pathophysiology, clinical manifestations, and treatment strategies for acquired FXIII deficiencies.

Related Experiment Videos

  • Analysis of clinical significance of FXIII inhibitors and associated conditions.
  • Evaluation of the role of FXIII reduction in clinical symptoms and substitution treatment efficacy.

    • Main Results:

    • Acquired FXIII deficiency can arise from specific inhibitors or be secondary to other clinical conditions.
    • Severe FXIII deficiency due to inhibitors carries a high risk of hemorrhage and mortality, necessitating rapid intervention.
    • The impact of moderate FXIII reduction on clinical symptoms varies, and substitution treatment may be considered.

    Conclusions:

    • Acquired FXIII deficiencies require careful evaluation and tailored management strategies.
    • Early diagnosis and treatment of FXIII inhibitor-related deficiency are critical to reduce morbidity and mortality.
    • Further research is needed to clarify the role of FXIII in various clinical settings and optimize substitution therapies.